DOD Biotech (Thailand) Performance
| DOD Stock | 1.98 0.02 1.00% |
The firm shows a Beta (market volatility) of 0.73, which means possible diversification benefits within a given portfolio. As returns on the market increase, DOD Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding DOD Biotech is expected to be smaller as well. At this point, DOD Biotech Public has a negative expected return of -0.71%. Please make sure to confirm DOD Biotech's mean deviation, downside deviation, standard deviation, as well as the relationship between the semi deviation and coefficient of variation , to decide if DOD Biotech Public performance from the past will be repeated in the future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days DOD Biotech Public has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
| Begin Period Cash Flow | 143 M | |
| Total Cashflows From Investing Activities | -71.7 M |
DOD |
DOD Biotech Relative Risk vs. Return Landscape
If you would invest 308.00 in DOD Biotech Public on September 13, 2024 and sell it today you would lose (110.00) from holding DOD Biotech Public or give up 35.71% of portfolio value over 90 days. DOD Biotech Public is producing return of less than zero assuming 2.1874% volatility of returns over the 90 days investment horizon. Simply put, 19% of all stocks have less volatile historical return distribution than DOD Biotech, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
DOD Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for DOD Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as DOD Biotech Public, and traders can use it to determine the average amount a DOD Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3247
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DOD |
Estimated Market Risk
| 2.19 actual daily | 19 81% of assets are more volatile |
Expected Return
| -0.71 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.32 actual daily | 0 Most of other assets perform better |
Based on monthly moving average DOD Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of DOD Biotech by adding DOD Biotech to a well-diversified portfolio.
DOD Biotech Fundamentals Growth
DOD Stock prices reflect investors' perceptions of the future prospects and financial health of DOD Biotech, and DOD Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DOD Stock performance.
| Return On Equity | 0.04 | |||
| Return On Asset | 0.0281 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.10 % | |||
| Current Valuation | 2.04 B | |||
| Shares Outstanding | 410 M | |||
| Price To Book | 1.47 X | |||
| Price To Sales | 2.55 X | |||
| Revenue | 1.02 B | |||
| EBITDA | 338.82 M | |||
| Total Debt | 19.31 M | |||
| Book Value Per Share | 3.03 X | |||
| Cash Flow From Operations | 145 M | |||
| Earnings Per Share | 0.12 X | |||
| Total Asset | 1.63 B | |||
About DOD Biotech Performance
By examining DOD Biotech's fundamental ratios, stakeholders can obtain critical insights into DOD Biotech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that DOD Biotech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Things to note about DOD Biotech Public performance evaluation
Checking the ongoing alerts about DOD Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DOD Biotech Public help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| DOD Biotech Public generated a negative expected return over the last 90 days | |
| DOD Biotech Public may become a speculative penny stock | |
| About 48.0% of the company shares are held by company insiders |
- Analyzing DOD Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DOD Biotech's stock is overvalued or undervalued compared to its peers.
- Examining DOD Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DOD Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of DOD Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DOD Biotech's stock. These opinions can provide insight into DOD Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in DOD Stock
DOD Biotech financial ratios help investors to determine whether DOD Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DOD with respect to the benefits of owning DOD Biotech security.